Neuromodulation for Post-Traumatic Stress Disorder

NCT02377089 | Completed Results DMC

• 1 other identifier: W81XWH-14-2-0125
• Study Type: interventional
• Target: 72
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators propose to use a clinical trial to test Trigeminal Nerve Stimulation (TNS) to examine the efficacy of TNS as a new treatment for Post Traumatic Stress Disorder (PTSD) in veterans. Recruitment will take place at the PTSD Outpatient Clinic at the Veterans Affair Greater Los Angeles (VA GLA). Study participants will be asked to complete, at most, 9 assessments/questionnaires regarding their PTSD symptoms and quality of life, use the TNS device every night for 8 hours, log their use of the device, and attend weekly visits to monitor safety and complete assessments. Each subject will be asked to attend 8 visits over the course of 8 weeks. Subjects who receives the sham-controlled treatment will have an additional follow-up phone visit 4 weeks after the week 8 endpoint to examine symptom improvements. Enrollment and subject-related procedures are projected to take approximately 36 months. Preparations for clinical trial, clinical trial/study procedures and data analysis will occupy a 6 month period, a 36 month period, and a 6 month period, respectively. The duration of this project is approximately 4 years.

Conditions

Post-Traumatic Stress Disorder

Keywords

Trigeminal Nerve Stimulation; Post-Traumatic Stress Disorder

Outcome Measures

Primary Outcomes (1)

• Treatment Efficacy as Measured by Change in Clinician-Administered Post Traumatic Stress Disorder Score for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition(DSM-V) at Baseline and Week 8 Visit

  Treatment efficacy as measured by change in Clinician-Administered Post Traumatic Stress Disorder score for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition at baseline and Week 8 visit. This is a 30-item questionnaire with minimum and maximum score values ranging from 0 to 80. Higher scores indicate a worse outcome and lower scores indicate better outcome.

  8 weeks (Baseline visit and Week 8 visit)

Secondary Outcomes (1)

• Treatment Efficacy as Measured by Change in Score on Beck Depression Inventory-II Assessment Scores.

  8 weeks ((Baseline visit and Week 8 visit)

Study Arms (2)

Sham

SHAM COMPARATOR

The stimulators are the same device for the active and sham treatment conditions.

Device: Placebo

Active

ACTIVE COMPARATOR

The stimulators are the same device for the active and sham treatment conditions.

Device: Trigeminal Nerve Stimulation

Interventions

Trigeminal Nerve Stimulation DEVICE

Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the active frequency of 120 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.

Also known as: TNS

Active

Placebo DEVICE

Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the sham frequency of 0 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.

Sham

Eligibility Criteria

• Age: 21 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years old and be a patient in the Post Traumatic Stress Disorder(PTSD) Clinic at the Veterans Affair Greater Los Angeles
• have experienced trauma while serving in a war zone in Iraq or Afghanistan
• meet The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria for current war zone-related PTSD with a duration of at least 3 months
• have completed a course of Prolonged Exposure(PE) therapy in the Resident Psychotherapy Program in the PTSD Clinic within six months of enrollment and with significant residual PTSD symptoms as evidenced by a Clinician-Administered PTSD Scale score \>50
• consent to be randomized to active or sham Trigeminal Nerve Stimulation treatment
• if receiving medication for depression, anxiety, sleep, or mood stabilization, must have been on stable dose for at least six weeks prior to randomization.

You may not qualify if:

• current substance abuse not in remission for at least 3 months
• a history of bipolar, schizophrenia, other psychotic disorder, or dementia
• current suicidal or homicidal ideation requiring hospitalization, or suicide attempt within six months
• report of severe Traumatic Brain Injury (TBI) with coma duration (30 minutes or more) during the screening interview and/or duration of post - traumatic amnesia (1hour or greater) on the Post-traumatic Amnesia Questionnaire (PTAQ)
• evidence of receiving antidepressant, antianxiety, antipsychotic, or mood-stabilizer medication where the dose has not been stable for a minimum of six weeks prior to entering the randomization
• evidence of receiving psychosocial or medication treatment through a clinic or facility other than the VA GLA PTSD Clinic.
• infection or loss of integrity of skin over the forehead, where the electrode pads will be placed.

Sponsors & Collaborators

• University of California, Los Angeles: lead
• VA Greater Los Angeles Healthcare System: collaborator
• United States Department of Defense: collaborator

Study Sites (1)

VA PTSD Clinic

Los Angeles, California, 90073, United States

Location

MeSH Terms

Conditions

Stress Disorders, Post-Traumatic

Condition Hierarchy (Ancestors)

Stress Disorders, Traumatic; Trauma and Stressor Related Disorders; Mental Disorders

Results Point of Contact

• Title: Andrew F. Leuchter
• Organization: UCLA Semel Insititute

afl@ucla.edu

310-825-0207

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Psychiatry and Biobehavioral Sciences

Study Record Dates

• First Submitted: November 17, 2014
• First Posted: March 3, 2015
• Study Start: May 1, 2014
• Primary Completion: October 20, 2020
• Study Completion: October 20, 2020
• Last Updated: June 8, 2022
• Results First Posted: June 8, 2022

Record last verified: 2022-05

Locations

US (1)